2026-09-25T06:30:15Zhttps://univendspace.univen.ac.za/server/oai/request

oai:univendspace.univen.ac.za:11602/30042026-02-09T09:42:20Zcom_11602_1924com_11602_1914com_11602_1897com_11602_737col_11602_2142col_11602_738

Ramaite, I. D. I. van Ree, T. Mogolla, Shibe Ncina 2025 2025-10-16T07:10:39Z 2025-10-16T07:10:39Z 2025-09-05 Mogolla, S.N. 2025. Design and synthesis of potential chrome=based anti-tuberculosis agents. . . https://univendspace.univen.ac.za/handle/11602/3004 Mogolla SN. Design and synthesis of potential chrome=based anti-tuberculosis agents. []. , 2025 [cited yyyy month dd]. Available from: Mogolla, S. N. (2025). <i>Design and synthesis of potential chrome=based anti-tuberculosis agents</i>. (). . Retrieved from Mogolla, Shibe Ncina. <i>"Design and synthesis of potential chrome=based anti-tuberculosis agents."</i> ., , 2025. TY - Dissertation AU - Mogolla, Shibe Ncina AB - This dissertation describes the design and synthesis of 4-(4-oxochromen-3-yl)-3,4-dihydropyrimidin-2-one derivatives and the assessment of their biological activity against a strain of the causative agent of TB. In this investigation, two classes of chromone-based compounds were synthesised. Different reactions were exploited to synthesise target compounds. In the first route, a Vilsmeier-Haack reaction was applied to convert the 3,5-disubstituted/unsubstituted 2-hydroxyacetophenones to corresponding 6,8-disubstituted/unsubstituted chromone-3-carbaldehydes. The 6,8-disubstituted/unsubstituted chromone-3-carbaldehydes were oxidized to afford 6,8-disubstituted/unsubstituted chromone-3-carboxylic acids with poor percentage yield 15-28%. Additionally, a second series of compounds were obtained by employing the Biginelli reaction to afford ethyl 6-hydroxy-4-(6-substituted/unsubstituted chromon-3-yl)-2-oxo-6-trifluoromethyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate derivatives with moderate to good percentage yield of 53 – 74%. Ethyl 6-hydroxy-4-(6-substituted/unsubstituted chromon-3-yl)-2-oxo-6-trifluoromethyl-1,2,3,4-tetrahydropyrimidine-5-carboxylates were successfully dehydrated to ethyl 4-(6-substituted/unsubstituted chromon-3-yl)-2-oxo-6-trifluoromethyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate derivatives using a Dean-Stark method at 140 °C, purified by recrystallization. All target compounds were purified by recrystallization and flash chromatography, and then characterized using NMR and FTIR, LC-MS and HRMS. After fully characterizing target compounds, they were screened for activity against the Mtb H37Rv clinical strain. Three media were used for screening and MABA was used for quantitative analysis. Unfortunately, all compounds tested were inactive with an MIC value ˃62.5 μM. Ethyl 2-oxo-4-(4-oxo-6-phenyl-4H-chromen-3-yl)-6-(trifluoromethyl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate with reported MIC of 3.39 μM also did not show any activity. The discrepancies in the results could be due to differences in media used, incubation conditions, bacteria or contamination. Derivatives with 4-substututed phenyl substituents, were insoluble with solubility <5 μM. The OH group was critical for solubility as removing it resulted in poor solubility. Ethyl 4-(6-substituted/unsubstituted chromon-3-yl)-2-oxo-6-trifluoromethyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate derivatives did not show any cytotoxicity against HepG2 cell line, with all compounds showing ˃50 μM toxicity. DA - 2025-09-05 DB - ResearchSpace DP - Univen KW - Chromones KW - Vilsmeier-Haack formylation KW - Mycobacterium tuberculosis KW - Hofmann rearrangement KW - Drug resistance. LK - https://univendspace.univen.ac.za PY - 2025 T1 - Design and synthesis of potential chrome=based anti-tuberculosis agents TI - Design and synthesis of potential chrome=based anti-tuberculosis agents UR - ER - MSc in Chemistry Department of Chemistry This dissertation describes the design and synthesis of 4-(4-oxochromen-3-yl)-3,4-dihydropyrimidin-2-one derivatives and the assessment of their biological activity against a strain of the causative agent of TB. In this investigation, two classes of chromone-based compounds were synthesised. Different reactions were exploited to synthesise target compounds. In the first route, a Vilsmeier-Haack reaction was applied to convert the 3,5-disubstituted/unsubstituted 2-hydroxyacetophenones to corresponding 6,8-disubstituted/unsubstituted chromone-3-carbaldehydes. The 6,8-disubstituted/unsubstituted chromone-3-carbaldehydes were oxidized to afford 6,8-disubstituted/unsubstituted chromone-3-carboxylic acids with poor percentage yield 15-28%. Additionally, a second series of compounds were obtained by employing the Biginelli reaction to afford ethyl 6-hydroxy-4-(6-substituted/unsubstituted chromon-3-yl)-2-oxo-6-trifluoromethyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate derivatives with moderate to good percentage yield of 53 – 74%. Ethyl 6-hydroxy-4-(6-substituted/unsubstituted chromon-3-yl)-2-oxo-6-trifluoromethyl-1,2,3,4-tetrahydropyrimidine-5-carboxylates were successfully dehydrated to ethyl 4-(6-substituted/unsubstituted chromon-3-yl)-2-oxo-6-trifluoromethyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate derivatives using a Dean-Stark method at 140 °C, purified by recrystallization. All target compounds were purified by recrystallization and flash chromatography, and then characterized using NMR and FTIR, LC-MS and HRMS. After fully characterizing target compounds, they were screened for activity against the Mtb H37Rv clinical strain. Three media were used for screening and MABA was used for quantitative analysis. Unfortunately, all compounds tested were inactive with an MIC value ˃62.5 μM. Ethyl 2-oxo-4-(4-oxo-6-phenyl-4H-chromen-3-yl)-6-(trifluoromethyl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate with reported MIC of 3.39 μM also did not show any activity. The discrepancies in the results could be due to differences in media used, incubation conditions, bacteria or contamination. Derivatives with 4-substututed phenyl substituents, were insoluble with solubility <5 μM. The OH group was critical for solubility as removing it resulted in poor solubility. Ethyl 4-(6-substituted/unsubstituted chromon-3-yl)-2-oxo-6-trifluoromethyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate derivatives did not show any cytotoxicity against HepG2 cell line, with all compounds showing ˃50 μM toxicity. NRF and South African Medical Research Council 1 online resource (115 leaves) : color illustrations en PDF University of Venda Chromones Vilsmeier-Haack formylation Mycobacterium tuberculosis Hofmann rearrangement Drug resistance. UCTD Design and synthesis of potential chrome-based anti-tuberculosis agents Dissertation embargo